| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MCAM | Synonyms | CD146, HEMCAM, METCAM, MUC18, MelCAM | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q23.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | melanoma cell adhesion molecule | ||||
| GTO ID | GTC2839 |
| Trial ID | NCT05117138 |
| Disease | Head and Neck Squamous Cell Carcinoma | Lung Non-Small Cell Carcinoma | Melanoma |
| Altered gene | CD19|MUC18 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | AMT-116 CAR-T cells|AMT-253 CAR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors |
| Year | 2021 |
| Country | China |
| Company sponsor | Beijing Immunochina Medical Science & Technology Co., Ltd. |
| Other ID(s) | MHSW016 |
| Cohort1: NSCLC/HNSCC | |||||||
|
|||||||
| Cohort2: Melanoma | |||||||
|
|||||||